Sign Up Today and Learn More About Emergex Vaccines Stock
Invest in or calculate the value of your shares in Emergex Vaccines or other pre-IPO companies through EquityZen's platform.
Emergex Vaccines Stock (EMVA)
Pioneering a new approach to vaccine development and manufacturing using cutting-edge technologies to produce novel synthetic vaccines.
About Emergex Vaccines Stock
Founded
2016
Industries
Software, Artificial Intelligence, Data and Analytics
Emergex Vaccines offer affordable, practical and effective vaccines on-demand, which are suited to low resource environments, disproportionately affected by pandemics. These vaccines will be used to create a clinical grade international vaccine repository that will act as a first line of defence in the case of existing and newly emerging infectious disease outbreaks.
Emergex Vaccines Press Mentions
Stay in the know about the latest news on Emergex Vaccines
Emergex Announces MHRA Approval of MIA (IMP) Manufacturing and Import Authorisation License
globenewswire • Jun 25, 2024
Emergex Vaccines on LinkedIn: #dengue #emergex #rna #tcell
linkedin • May 20, 2024
Emergex Vaccines on LinkedIn: #emergex #id #rnavirus #tcell
linkedin • Apr 06, 2024
Emergex Vaccines expands at Milton Park
thebusinessmagazine • Mar 02, 2024
Emergex Announces R&D Collaboration with DEKA Research & Development Corp. for Assessment of Emergex's ...
globenewswire • Mar 02, 2024
Investors in Emergex Vaccines
Discover investors in Emergex Vaccines stock and explore their portfolio companies
Emergex Vaccines Management
Leadership team at Emergex Vaccines
Founder and CEO
Thomas Rademacher
Founder, Executive Director, Chief Operating Officer
Storme Moore-Thornicroft
Join now and verify your accreditation status to gain access to:
- Emergex Vaccines current valuation
- Emergex Vaccines stock price
- Available deals in Emergex Vaccines and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in Emergex Vaccines stock?
Accredited investors can buy pre-IPO stock in companies like Emergex Vaccines through EquityZen funds. These investments are made available by existing Emergex Vaccines shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Emergex Vaccines stock?
Shareholders can sell their Emergex Vaccines stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
